Mylius, Veit
Möller, Jens Carsten
Bohlhalter, Stephan
Ciampi de Andrade, Daniel
Perez Lloret, Santiago http://orcid.org/0000-0001-9069-6512
Article History
Accepted: 18 May 2021
First Online: 5 July 2021
Declarations
:
: No sources of funding were received for the preparation of this article.
: Veit Mylius consulted for Abbvie, and received research grants from Zambon and Mundipharma. He further received support from Boston Scientific, Licher MT, Abbvie, and Medtronic. Santiago Perez-Lloret received honoraria from IPMDS and consulted for ELEA laboratories and Inmunova Laboratories. Jens Carsten Möller, Stephan Bohlhalter, and Daniel Ciampi de Andrade have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: VM drafted the first version, DCDA and SPL drafted parts of the manuscript. JCM and SB corrected and improved the first version. All authors improved the subsequent versions and gave their final consent.